The sale of its proteomic tools business to Bio-Rad may be in a holding pattern, but Ciphergen is already touting itself as a diagnostics firm.
 
One week after the anticipated Nov. 1 completion date, the sale of Ciphergen’s Surface Enhanced Laser Desorption/Ionization technology and other products to Bio-Rad still remained delayed. But in comments to analysts this week, Ciphergen CEO Gail Page made it clear that the company is forging ahead in its new identity as a specialty diagnostic firm.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.